EGFR mutation‐positive lung cancer patients, for example, were found to not only be unresponsive to PD‐1/PD‐L1 inhibition (Calles et al, 2020) but even to hyper‐progress after immunotherapy (Kato et al, 2017). The gene discussed is EGFR; the disease is lung carcinoma.